Christopher Logan
Primary Care · San Antonio, TXNPI 1639710148
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 469 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 469 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$868
- Lilly USA, LLC$774
- Bayer$610
- Pfizer$511
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$2503%
- Food & beverage$8,23097%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 118 | $1,929 |
| Novo Nordisk | 70 | $1,136 |
| AstraZeneca | 31 | $868 |
| Lilly USA, LLC | 50 | $774 |
| Bayer | 29 | $610 |
| Pfizer | 40 | $511 |
| Antares Pharma, Inc. | 18 | $325 |
| GSK | 17 | $299 |
| Shield Therapeutics Inc | 15 | $259 |
| Biohaven Pharmaceuticals, Inc. | 6 | $203 |
| Axsome Therapeutics, Inc. | 6 | $194 |
| Otsuka America Pharmaceutical, Inc. | 2 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $135 |
| Amarin Pharma, Inc. | 7 | $128 |
| Exact Sciences | 6 | $124 |
| Johnson & Johnson | 4 | $78 |
| Halozyme Inc | 3 | $63 |
| Acerus Pharmaceuticals Corporation | 4 | $59 |
| Clarus Therapeutics Inc. | 4 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $55 |
| Azurity Pharmaceuticals, Inc. | 3 | $50 |
| Astellas Pharma US Inc | 3 | $49 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Merck | 3 | $48 |
| Arbor Pharmaceuticals, Inc. | 3 | $48 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Amgen | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Tolmar, Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Corcept Therapeutics | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,491 in reported general payments places this provider in the 95th percentile of 563 primary care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $52,082 |
| JardianceEmpagliflozin | 21 | $32,025 |
| FarxigaDapagliflozin Propanediol | 23 | $28,721 |
| KerendiaFinerenone | 21 | $28,452 |
| MounjaroTirzepatide | 15 | $15,408 |
| Liothyronine Sodium | 51 | $2,297 |
| Ezetimibe | 62 | $2,075 |
| Np ThyroidThyroid,pork | 23 | $2,028 |
| Testosterone | 12 | $1,567 |
| Telmisartan | 62 | $1,057 |
| Testosterone Cypionate | 11 | $578 |
| Montelukast Sodium | 18 | $513 |
| Olmesartan Medoxomil | 38 | $512 |
| Levothyroxine Sodium | 56 | $488 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 20 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,136 | $52,08239 claims |
| AstraZenecaFarxiga | $868 | $28,72123 claims |
| BayerKerendia | $610 | $28,45221 claims |
| Lilly USA, LLCMounjaro | $774 | $15,40815 claims |
| AbbVieSynthroid | $1,929 | $25212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 563 primary care providers in Texas.
Other primary care in San Antonio
- Phillip GulleySan Antonio$23K
- Charlotte BallardSan Antonio$9K
- Lydia Chapa WilsonSan Antonio$7K
- Jing LiSan Antonio$6K
- Lauryn SaenzSan Antonio$5K
- Brittany CurrySan Antonio$4K
- Martha RuizSan Antonio$3K
- Ryan WenclSan Antonio$3K
- Gabriella MutschlechnerSan Antonio$3K
- Mary GibbensHouston$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.